tiprankstipranks
Trending News
More News >
Vijaya Diagnostic Centre Ltd. (IN:VIJAYA)
:VIJAYA
India Market
Advertisement

Vijaya Diagnostic Centre Ltd. (VIJAYA) AI Stock Analysis

Compare
1 Followers

Top Page

IN:VIJAYA

Vijaya Diagnostic Centre Ltd.

(VIJAYA)

Rating:66Neutral
Price Target:
₹1,212.00
▲(14.65% Upside)
Vijaya Diagnostic Centre Ltd. demonstrates strong financial performance with robust revenue growth and high profitability margins. The technical analysis indicates bullish momentum, but the stock appears overbought, warranting caution. Valuation factors suggest the stock might be overvalued with a high P/E ratio and low dividend yield. The overall stock score reflects these strengths and risks.

Vijaya Diagnostic Centre Ltd. (VIJAYA) vs. iShares MSCI India ETF (INDA)

Vijaya Diagnostic Centre Ltd. Business Overview & Revenue Model

Company DescriptionVijaya Diagnostic Centre Ltd. (VIJAYA) is a leading diagnostic chain in India, operating in the healthcare sector. It provides a comprehensive range of diagnostic services, including pathology and radiology tests, to assist in medical diagnoses. The company is dedicated to delivering high-quality diagnostic services through its network of centers equipped with advanced technology and a team of experienced healthcare professionals.
How the Company Makes MoneyVijaya Diagnostic Centre Ltd. makes money primarily through the provision of diagnostic testing services across its network of centers. Key revenue streams include fees charged for pathology tests, which involve the examination of blood, urine, and other bodily fluids, and radiology tests such as X-rays, MRIs, and CT scans. The company's revenue is driven by the demand for these diagnostic services from individual patients, healthcare providers, and corporate clients. Additionally, Vijaya Diagnostic Centre may engage in partnerships with hospitals and clinics to provide outsourced diagnostic services, contributing to its earnings.

Vijaya Diagnostic Centre Ltd. Financial Statement Overview

Summary
Vijaya Diagnostic Centre Ltd. exhibits strong financial performance with significant revenue growth, high profitability margins, and efficient cash flow management. The balance sheet reflects low leverage and a solid equity standing, while cash flows demonstrate robust trends and solid operational cash generation.
Income Statement
85
Very Positive
The company demonstrates strong revenue growth with a 24.38% increase from 2024 to 2025. Gross profit margin is impressive at 87.58%, and net profit margin has improved to 21.00%. EBIT and EBITDA margins are robust at 71.10% and 40.10%, respectively, indicating efficient operations and cost management. Overall, the income statement reflects positive growth and profitability trends.
Balance Sheet
78
Positive
The balance sheet shows a solid equity base with a debt-to-equity ratio of 0.40, which indicates low leverage. The company maintains a good equity ratio of 62.47%, highlighting financial stability. Return on equity is strong at 17.98%, reflecting effective use of equity to generate profits. The balance sheet is healthy, though there is room for improvement in reducing liabilities further.
Cash Flow
82
Very Positive
Operating cash flow is strong, translating into a high operating cash flow to net income ratio of 1.57. Free cash flow shows positive growth, increasing by 35.20% from the previous period. The free cash flow to net income ratio of 0.90 indicates effective cash management and ability to generate cash from operations. Overall, cash flow is robust, supporting the company's growth and operational needs.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.81B6.81B5.48B4.59B4.62B3.76B
Gross Profit5.53B5.97B4.61B4.00B3.91B3.19B
EBITDA2.85B2.73B2.39B1.96B2.16B1.77B
Net Income1.43B1.43B1.19B846.32M1.10B844.78M
Balance Sheet
Total Assets12.74B12.74B9.83B8.53B7.13B5.41B
Cash, Cash Equivalents and Short-Term Investments2.33B2.33B1.82B2.55B2.25B2.20B
Total Debt3.20B3.20B2.59B2.48B1.83B1.41B
Total Liabilities4.74B4.74B3.23B3.07B2.44B1.82B
Stockholders Equity7.96B7.96B6.57B5.45B4.68B3.59B
Cash Flow
Free Cash Flow0.001.29B953.37M397.69M356.50M975.07M
Operating Cash Flow0.002.24B1.83B1.65B1.58B1.30B
Investing Cash Flow0.00-1.82B-1.42B-1.10B-1.23B-1.30B
Financing Cash Flow0.00-520.48M-445.50M-419.12M-305.72M-487.69M

Vijaya Diagnostic Centre Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1057.15
Price Trends
50DMA
1010.11
Positive
100DMA
1001.67
Positive
200DMA
1027.39
Positive
Market Momentum
MACD
14.59
Positive
RSI
50.40
Neutral
STOCH
14.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIJAYA, the sentiment is Positive. The current price of 1057.15 is below the 20-day moving average (MA) of 1062.32, above the 50-day MA of 1010.11, and above the 200-day MA of 1027.39, indicating a neutral trend. The MACD of 14.59 indicates Positive momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 14.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VIJAYA.

Vijaya Diagnostic Centre Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
₹107.71B71.70
0.10%22.34%20.75%
64
Neutral
₹108.55B70.98
0.71%12.86%10.42%
63
Neutral
₹26.05B32.35
0.31%13.78%32.19%
61
Neutral
₹93.53B252.00
16.85%-29.52%
58
Neutral
₹34.11B26.07
22.04%
51
Neutral
$7.43B-0.36-45.45%2.27%22.98%-2.34%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,057.15
233.33
28.32%
IN:HCG
HealthCare Global Enterprises Ltd.
681.45
326.45
91.96%
IN:KRSNAA
Krsnaa Diagnostics Limited
798.70
140.56
21.36%
IN:METROPOLIS
Metropolis Healthcare Ltd.
2,126.70
144.85
7.31%
IN:UNICHEMLAB
Unichem Laboratories Limited
512.70
-43.90
-7.89%

Vijaya Diagnostic Centre Ltd. Corporate Events

Vijaya Diagnostic Centre Secures Shareholder Approval for Key Resolution
Apr 28, 2025

Vijaya Diagnostic Centre Ltd. announced the successful passing of a resolution by its equity shareholders during a court-convened general meeting. The resolution was approved by a majority of shareholders, including both promoter and public shareholders, indicating strong support for the company’s proposed actions. This outcome may positively impact the company’s strategic operations and reinforce its market position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025